2014 Fiscal Year Final Research Report
Identification of cancer-derived peptides as potential candidates for the development of anti-cancer vaccines for prostate cancer patients
| Project/Area Number |
24592416
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Kinki University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Keywords | 前立腺癌 / ペプチドワクチン / HLA-A3 |
|---|
| Outline of Final Research Achievements |
EZH2-derived peptides applicable to prostate cancer patients with HLA-A3 supertype alleles were identified in order to expand the possibility of an anti-cancer vaccine, because the peptide vaccine candidates receiving the most attention thus far have been the HLA-A2 and HLA-A24 alleles. Five EZH2-derived peptides that were prepared based on the binding motif to the HLA-A3 supertype alleles (HLA-A11,-A31, and -A33) were screened for the potential to induce peptide-specific cytotoxic T lymphocytes (CTLs) from HLA-A3 supertype+ prostate cancer patients. As a result, EZH2733-741 efficiently induced peptide-specific and cancer-reactive CTLs. Their cytotoxicity toward prostate cancer cells was ascribed to peptide-specific and CD8+ T cells. These results indicate that the EZH2733-741 peptide could be promising candidates for peptide-based immunotherapy for HLA-A3 supertype+ prostate cancer patients.
|
| Free Research Field |
泌尿器科学
|
